Published in final edited form as:

Radiother Oncol. 2014 October ; 113(1): 89–94. doi:10.1016/j.radonc.2014.08.017.

Quality of Life Outcomes in Proton and Photon Treated Pediatric Brain Tumor Survivors

Torunn I. Yock, MD MCH,

Department of Radiation Oncology, Massachusetts General Hospital, 55 Fruit Street, Proton Center, Room 110, Boston, MA 02114, PH: 617 726-6876, FAX: 617-724-9532

Sundeep Bhat, MD,

Department of Emergency Medicine, Kaiser Permanente, Santa Clara Medical Center, 700 Lawrence Expy, Santa Clara, CA 95051

Jackie Szymonifka, MA,

Biostatistics Unit, Department of Medicine, Massachusetts General Hospital, 50 Staniford St., Boston, MA 02114

Beow Y. Yeap, ScD,

Biostatistics Unit, Department of Medicine, Massachusetts General Hospital, 50 Staniford St., Boston, MA 02114

Jennifer Delahaye, MA,

Center for Child and Adolescent Health Policy, Massachusetts General Hospital, 100 Cambridge St., Boston, MA 02114

Sarah S. Donaldson, MD,

Stanford Cancer Center, Department of Radiation Oncology, 875 Blake Wilbur Dr. G226, Stanford, CA 94305-5847

Shannon M. MacDonald, MD,

Department of Radiation Oncology, Massachusetts General Hospital, Proton Center, 55 Fruit St., Boston, MA 02114

Margaret B. Pulsifer, PhD,

Department of Psychiatry, Massachusetts General Hospital, 1 Bowdoin Square, Boston, MA 02114

© 2014 Elsevier Ireland Ltd. All rights reserved.

Correspondence to: Torunn I. Yock, tyock@partners.org.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.

Financial Disclosures: None of the authors have any conflicts of interest with the exception of Nancy J. Tarbell, MD. Dr. Tarbell's husband is on the Medical Advisory Board for Procure.

This paper was presented at the Annual Meetings of the International Society of Paediatric Oncology (SIOP) London UK, 5-8 October 2012.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Kristen S. Hill, MS,

Center for Child and Adolescent Health Policy, Massachusetts General Hospital, 100 Cambridge St., Boston, MA 02114

Thomas F. DeLaney, MD,

Department of Radiation Oncology, Massachusetts General Hospital, Proton Center, 55 Fruit Street, Boston, MA 02114

David Ebb, MD,

Department of Pediatric Oncology, Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114

Mary Huang, MD,

Department of Pediatric Oncology, Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114

Nancy J. Tarbell, MD,

Department of Radiation Oncology, Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114

Paul Graham Fisher, MD, and

Stanford University Medical Center, Department of Neurology, 300 Pasteur Drive, Room A347, Palo Alto, CA 94305

Karen A. Kuhlthau, PhD

Center for Child and Adolescent Health Policy, Massachusetts General Hospital, Department of Pediatrics, Harvard Medical School, 100 Cambridge St., Boston, MA 02114

Torunn I. Yock: tyock@partners.org

Abstract

Background—Radiotherapy can impair Health Related Quality of Life (HRQoL) in survivors of childhood brain tumors, but proton radiotherapy (PRT) may mitigate this effect. This study compares HRQoL in PRT and photon (XRT) pediatric brain tumor survivors.

Methods—HRQoL data was prospectively collected on PRT-treated patients age 2-18 treated at Massachusetts General Hospital (MGH). Cross-sectional PedsQL data from XRT treated Lucile Packard Children's Hospital (LPCH) patients provided the comparison data.

Results—Parent proxy HRQoL scores were reported at 3 years for the PRT cohort (PRT-C) and 2.9 years (median) for the XRT cohort (XRT-C). The total core HRQoL score for the PRT-C, XRT-C, and normative population differed from one another and was 75.9, 65.4 and 80.9 respectively ($p=0.002$; $p=0.024$; $p<0.001$). The PRT-C scored 10.3 and 10.5 points higher than the XRT-C in the physical (PhSD) and psychosocial (PsSD) summary domains of the total core score (TCS, $p=0.015$; $p=0.001$). The PRT-C showed no difference in PhSD compared with the normative population, but scored 6.1 points less in the PsSD ($p=0.003$). Compared to healthy controls, the XRT-C scored lower in all domains ($p<0.001$).

Conclusions—The HRQoL of pediatric brain tumor survivors treated with PRT compare favorably to those treated with XRT and similar to healthy controls in the PhSD.

Keywords

pediatric brain tumor; quality of life; PedsQL; QoL; proton; photon; radiation; late effects; outcomes

Introduction

Although radiotherapy is an essential part of treatment for many pediatric brain tumor patients, it is also known to contribute to late side effects in survivors.¹ These late health effects are due, in part, to the radiation of uninvolved tissues in the beam path that can negatively affect normal development and function. Some of these late effects include neurocognitive or behavioral effects, endocrine abnormalities, vascular effects,²⁻⁴ and second tumors. The severity of radiation-related late morbidities is associated with younger age at treatment, higher doses of radiation and larger volumes of normal tissue receiving significant radiation dose.⁵⁻⁷ These late effects are associated with lower direct and indirect measures of Health-Related Quality of Life (HRQoL).^{3, 8-12} Proton radiotherapy can deliver less radiation dose to normal tissues than photon radiotherapy, because of the underlying physics intrinsic to its dose deposition and when compared with external beam photon techniques.^{13, 14-16} Because of the dose sparing to normal tissues, it has been widely hypothesized that the lower radiation dose to normal tissue may reduce the incidence and/or severity of late effects.¹⁷

Growing evidence has begun to document the health outcome benefit of proton radiotherapy in the pediatric cancer population.^{15, 18, 19} However, it is important to determine whether these health benefits translate into improved HRQoL. Thus, this study compares HRQoL outcomes in proton and photon treated cohorts²⁰.

Methods

HRQoL Data on Proton Cohort

Primary prospective HRQoL data were collected on pediatric brain tumor patients and survivors treated with proton therapy at MGH after approval by the MGH Institutional Review Board (IRB). All study subjects were recruited while receiving proton therapy at MGH and provided informed consent. Children between the ages of 2-18 and their parents were initially surveyed during treatment and then annually thereafter. All patients were assessed through parent-proxy report versions (PPR, for children age 2 and up) of the PedsQL Core Module.²¹⁻²⁴ Detailed methodology for this cohort was previously published.²⁰ In this study, the median year of radiation treatment was 2007 with the interquartile range (IQR) of 2006-2007.

HRQoL Data Photon (XRT) Cohort

At the time of embarking on this analysis, three published studies used the same PedsQL tool to assess HRQoL outcomes in pediatric brain tumor patients.^{9, 25, 26} However, only one study had sufficient numbers, a comparable time period to our study, and adequate clinical detail to merit comparison.²⁵ This resultant study is a collaborative effort between Harvard-

affiliated Massachusetts General Hospital (MGH) investigators and Stanford-affiliated Lucile Packard Children's Hospital (LPCH) investigators in Palo Alto, California.

LPCH is a large, tertiary referral center and a highly regarded center of excellence in pediatric and radiation oncology. The LPCH data are derived from an IRB approved cross-sectional study administered to consenting patients and/or families in their routine follow up clinic from November 2001 to September 2002. The median radiation treatment year was 2000 (IQR: 1998-2001).

The PedsQL was administered to 134 brain tumor survivors who were 1-21 years of age at the time of treatment, 63 of whom had received *photon* radiation, completed the parent proxy-reported PedsQL, and were 2 to 18 years old at the time of treatment. Study recruits were assessed with the standard PPR version. Socioeconomic status (SES) indicators were not collected or analyzed in this cohort.

PedsQL Survey Instrument

The PedsQL is a commonly used and previously validated assessment of HRQoL for general populations of children as well as children with chronic health conditions. The PedsQL survey results in a score with a range from 0 to 100, with 100 representing the best quality of life. PedsQL total scores are computed and are divided into two major sub domains, physical summary score and the psychosocial summary score. The psychosocial summary score is further sub divided into 3 parts, emotional functioning, social functioning and school functioning, which are also reported here.²¹

Statistical Analysis

Patient demographics and basic clinical data are reported in Table 1. Fisher's exact test was used to compare the distribution of patient characteristics between the MGH and LPCH cohorts. Overall PedsQL scores and subscale scores for the two cohorts are shown in Table 2. PedsQL scores were further reported by diagnosis category (Table 3): medulloblastoma/PNET (M/PNET), ependymoma/high-grade glioma/(E/HGG), low-grade glioma (LGG), and germ cell tumors (GCT). Figures for other low-grade neoplasm (LGN) are shown but, due to small sample size, should be interpreted with caution. Mean scores for the core module, including its subscales, are reported. Core scores from Tables 2 and 3 are graphically represented in Figure 1a and b.

Two-sample t-tests were used to determine if the scores from the two cohorts were significantly different, while a one-sample test was used to compare the scores from each cohort to those from a normative pediatric population.²⁷ As the marginal error rates are of primary interest, rather than an experiment-wise rate, the data analysis in Tables 2 and 3 has not been adjusted for multiple comparisons. All analyses were conducted using SAS software (Version 9.2; Copyright (c) 2002-2003 by SAS Institute Inc., Cary, NC, USA). All p-values are based on a two-sided hypothesis with significance testing at a 0.05 level.

Results

Fifty-seven pediatric brain tumor patients treated with PRT at the MGH were enrolled in the study between the years of 2004 and 2009 and completed the year 3 PedsQL assessment by October 2012. Sixty-three pediatric brain tumor patients treated with the XRT at LPCH were assessed between 2001 and 2002, in a cross-sectional style with a median follow-up of 2.9 years. Table 1 includes demographic and clinical characteristics of both cohorts. There is no significant difference between the cohorts in age, gender, surgery type, diagnostic group or tumor location; however, the LPCH cohort was more racially diverse and had a higher proportion of patients treated with a lower total dose of radiation. However, neither race nor radiation dose correlated with HRQoL outcomes.

The mean PedsQL total core score for the MGH proton cohort and for the LPCH photon cohort was 75.9 and 65.4 respectively ($p=0.002$). The proton cohort scored statistically better in the physical summary score (10.2 points; $p=0.015$) and the psychosocial summary domain (10.5 points, $p=0.001$). Within the sub-domains of the psychosocial summary score, the proton cohort scored better with regards to emotional and social functioning, but did not differ significantly from the photon group in school functioning, which was the sub-domain in which both cohorts scored the lowest (see Table 2).

The PedsQL scores from a normative healthy child population are also shown in Table 2. The proton cohort PedsQL score is 5.0 points lower than the normative healthy population ($p=0.024$) and the photon cohort is 13.3 points lower ($p<0.001$). In the proton cohort, the QoL difference from the normative population is largely driven by lower scores in the social and school functioning domains of the psychosocial summary score. There was no difference in the physical summary score domain between the proton and normative population cohorts. In contrast, in the photon cohort, the total core, physical summary and psychosocial summary scores, as well as the sub domains for the psychosocial summary score, were significantly lower than those for the normative population.

Table 3 shows the comparison of the HRQoL scores by tumor type in the MGH proton and LPCH photon cohorts. There were statistically significant differences in the total core score of the children treated for M/PNET, E/HGG, and LGG, favoring the proton cohorts. In the M/PNET cohort, the proton cohort scores 9.8 points better than the photon cohort for total core score ($p=0.05$). This difference is due to a larger difference in the physical summary score (13.0 points difference, $p=0.044$), compared with the psychosocial summary difference which was not significant, (7.8 points, $p=0.113$). In the E/HGG and LGG subgroups, the opposite was true. The largest contributor to the statistically significant difference in total core scores (17.9 points, $p=0.023$; 22.9 points, $p=0.017$ respectively) was the difference in the psychosocial summary scores (20.8, $p=0.006$; 24.5, $p=0.004$ respectively). There were no statistically significant differences in either the LGN or GCT groups.

Discussion

This is the first post-treatment comparison of HRQoL outcomes between pediatric proton and photon treated cohorts. This is also the first published comparison of HRQoL outcomes of a large prospectively followed cohort of pediatric patients treated with PRT with normative data from healthy children. The data reported here demonstrate the improved long-term HRQoL outcomes of children treated with PRT.

The proton cohort total core score (75.9) is 5 points less than the healthy population (80.9; $p=0.024$).²⁷ However, when it is put into the context of children with other pediatric chronic diseases such as diabetes (76.6), obesity (75.0) and asthma (68.8), or all cancers (including leukemias) (68.5), the PRT cohort is either the same or compares favorably.²⁴ In contrast, the photon cohort's total core score is 65.4 and 15.5 points lower than the healthy controls ($p<0.001$). This is consistent with different previously published cohort of all brain tumor patients (irrespective of radiotherapy use) 64.5.⁹

The post treatment HRQoL scores of the proton and photon treated cohorts were also compared directly. The proton cohort scored 10.5 points higher for the total core score and similarly in the physical summary and psychosocial summary scores (10.3 and 10.5 respectively). School functioning was the only sub-domain that was not different between the two cohorts and was the lowest score of both cohorts. Scores were 10-15.3 points less than what the normative population reports. These findings highlight an opportunity to improve the school experience for the childhood brain tumor survivor through better services and accommodations for any deficits related to the tumor and treatment. In many circumstances accommodations can be improved. Furthermore, the standard deviations (SDs) are relatively large (20.6 to 22.3) in this category suggesting variability in what the children experience in their schools. Interestingly, the SD is also relatively large in the data from the normative population which suggests heterogeneity in the school experience as well. It is reassuring for comparability that the SDs across the cohorts and in the various domains (see Table 2) are quite similar.

HRQoL scores differed between the proton and photon cohorts by diagnosis. Children with a diagnosis of M/PNET, E/HGG, or LGG, and treated with protons scored higher in overall core measures and in many of the sub-domains than children in the photon cohort. However, the pattern of differences within the domains of the total cores score varied by diagnosis. These differences may be explained if we presume that radiotherapy to the body has a greater relative effect on the physical health QoL outcomes (physical summary score) and radiotherapy to the brain has a greater relative effect on the psychosocial summary score.

In the M/PNET group, the difference was greater in the physical summary domain than the psychosocial summary domain. These patients are treated with craniospinal irradiation (CSI) which targets the whole brain and spine in order to sterilize the CSF where tumor cells circulate. With the proton modality, there is no exit dose to the body beyond the vertebral bodies, which better spares the bowels, heart and lungs as well as gonadal organs in females. Each of these organs receive between 50-80% of the prescription dose with photon techniques, compared to 0-5% with proton therapy. It is likely that tissue sparing with PRT

translates into better HRQoL in the physical domain. There was less of a difference in the psychosocial domain in the M/PNET patients, which is likely because both the proton and photon cohorts include many whole brain radiotherapy patients, where the dose sparing benefit to the normal brain with protons is diluted.

Using this same logic, it makes sense that it was the significant difference in psychosocial summary score that contributed most heavily to the significant difference in total core scores for the E/HGG and the LGG groups. In both these groups, typically only the involved tumor bed is irradiated, not the whole brain. Therefore, the difference in integral dose to the brain between the photon and proton cohorts will be greatest and is reflected in the psychosocial domain scores.

In contrast to the M/PNET, E/HGG and LGG groups, there was no statistically significant difference between cohorts for children with LGN or GCTs. Both of these comparisons are likely underpowered. In addition, the GCT cohort had higher median ages of (14 and 16 years respectively) when compared to the other disease types. Adverse health effects from radiation in the pediatric population are more pronounced the younger a child is at the time of radiotherapy. Therefore, differences may not be detectable at this older age.²⁸

Our data support the hypothesis that PRT produces better HRQoL outcomes compared to XRT, but does not prove it. HRQoL measures are correlated with health outcomes, which should also be better with proton therapy due to greater sparing of dose to normal tissues. Preliminary neurocognitive data of a proton cohort at 2 years of follow-up have shown that neurocognitive effects common in a mixed brain tumor population can be partially mitigated by the normal tissue sparing properties of protons.¹⁹ Three year follow-up data from a medulloblastoma cohort treated on a prospective trial also showed some reduction of late effects compared with published photon cohorts.²⁹ In a previous publication, we showed that HRQoL scores correlated with full scale IQ and scores on behavioral measures.²⁰ An important next step in analyzing outcomes of the pediatric brain tumor proton cohort would be to correlate health outcomes, such as hearing, endocrine function and other conditions, to HRQoL data to see if these measurable health outcomes are at least partly responsible for the higher HRQoL scores.

While the comparisons of HRQoL with the normative population and photon cohorts support the hypothesis that proton radiotherapy may help improve HRQoL, these comparisons must be interpreted in light of a number of limitations. First, the data collection methods at LPCH and MGH differ. The LPCH cohort study is a one-time cross sectional analysis with a median follow up of 2.9 years and the MGH data is based on a prospective longitudinal study using year three assessments to best match their follow up. Second, we are comparing data from two institutions with possibly different treatment approaches and who serve different patient populations. These potential differences could have an impact on HRQoL outcome. Third, the proton cohort likely includes a larger proportion of patients from a higher socio-economic status (SES), which may be associated with better HRQoL, although the data on the effects of SES on HRQoL are conflicting.^{3, 9, 10, 30} We do not have a method to account for this in the present study as neither site collected SES indicators. Fourth, radiation dose and volumes can affect health outcomes,³¹ with a significantly larger

proportion of the LPCH cohort receiving a lower radiation dose. However, this would be expected to skew the results in favor of the LPCH cohort, further strengthening the finding of improved HRQoL outcomes with PRT. On the other hand, volume of brain irradiated was not collected in either cohort, which has also been shown to affect health outcome. If either the proton or photon cohort had systematically larger volumes targeted, the results would be negatively skewed in that cohort. However, such a systematic skew would be unlikely. The analysis by disease type mitigates this potential confounding factor on our data set by separating out those patients most likely to have been treated with CSI (large volume) radiotherapy. However, for the patients receiving involved field or partial brain irradiation³¹ the proton cohort will have had less volume of normal brain irradiated since integral dose is cut by a factor of 2 or more on average.³² In fact, as previously addressed, we believe the higher psychosocial scores in patients treated with protons (E/HGG and LGG diagnostic groups) are due to the relative sparing of normal brain. Fifth, treatment options and techniques have changed over time, which could influence the results. The MGH cohort includes patients that were treated on average (median) 7 years later than the LPCH cohort. The more recently treated proton cohort at MGH may have benefited from improved techniques over time in all the treatment arenas, including surgery, chemotherapy and radiation therapy, which would skew the results to favor the proton cohort.

While this study is truly unique and the first of its kind, greater follow up is needed as late effects of treatment manifest over time.³³ The MGH prospective study will continue for at least 10 years after treatment and we are working to find an appropriate prospectively accrued photon comparison group. Additionally, this study uses parent reports for all cohorts including the normative data, which are both a strength and a weakness. There could be a parental bias in families who choose PRT. While patient reported outcomes remain the gold standard, both Varni et al. and our previous work have nevertheless shown that the parent proxy reports and child self reports are highly correlated.²⁰ The advantage here is that some patients, (e.g. the preliterate or neurologically impaired) can still participate in these HRQoL outcome studies. Parent reporting is a good proxy for HRQoL outcomes in children,^{20, 25, 27} and are notably better than provider or clinician reported outcomes, which is the only other alternative.

In summary, our findings show that HRQoL in a proton treated pediatric brain tumor cohort appear somewhat better than the HRQoL outcomes in a cohort of children treated with photons a few years earlier. Perhaps even more telling is HRQoL outcomes in the proton cohort are only slightly worse than that of the healthy child population and either comparable or better children with other chronic diseases.²⁴ Importantly, the direct comparison with the source data from the LPCH photon cohort supports (but does not prove) that proton radiotherapy may be making a positive difference in pediatric brain tumor survivors. However, given the limitations of the study discussed above, a direct and contemporary comparison of proton and photon cohorts with the same data collection methodology and accounting for SES status is a necessary next step to more fully evaluate the benefits of proton radiotherapy in pediatric brain tumor survivors.

Acknowledgments

Funding: Funding for the MGH project was supported by Award Number P01CA021239 from the National Cancer Institute. The project was also supported in part by the Susan McDaniel Brain Tumor Fund and the MGH Marathon Fund for Pediatric Cancer. Funding for the LPCH project was from the National Brain Tumor Foundation Pediatric Research Grant.

References

1. Armstrong GT, Stovall M, Robison LL. Long-term effects of radiation exposure among adult survivors of childhood cancer: results from the childhood cancer survivor study. *Radiat Res.* 2010; 174(6):840–50. [PubMed: 21128808]
2. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. *N Engl J Med.* 2006; 355(15):1572–82. [PubMed: 17035650]
3. Meeske KA, Patel SK, Palmer SN, Nelson MB, Parow AM. Factors associated with health-related quality of life in pediatric cancer survivors. *Pediatr Blood Cancer.* 2007; 49(3):298–305. [PubMed: 16779805]
4. Diller L, Chow EJ, Gurney JG, et al. Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings. *J Clin Oncol.* 2009; 27(14):2339–55. [PubMed: 19364955]
5. Laughton SJ, Merchant TE, Sklar CA, et al. Endocrine outcomes for children with embryonal brain tumors after risk-adapted craniospinal and conformal primary-site irradiation and high-dose chemotherapy with stem-cell rescue on the SJMB-96 trial. *J Clin Oncol.* 2008; 26(7):1112–8. [PubMed: 18309946]
6. Mulhern RK, White HA, Glass JO, et al. Attentional functioning and white matter integrity among survivors of malignant brain tumors of childhood. *J Int Neuropsychol Soc.* 2004; 10(2):180–9. [PubMed: 15012838]
7. Merchant TE, Hua CH, Shukla H, Ying X, Nill S, Oelfke U. Proton versus photon radiotherapy for common pediatric brain tumors: comparison of models of dose characteristics and their relationship to cognitive function. *Pediatr Blood Cancer.* 2008; 51(1):110–7. [PubMed: 18306274]
8. Packer RJ. Childhood brain tumors: accomplishments and ongoing challenges. *J Child Neurol.* 2008; 23(10):1122–7. [PubMed: 18952578]
9. Meeske K, Katz ER, Palmer SN, Burwinkle T, Varni JW. Parent proxy-reported health-related quality of life and fatigue in pediatric patients diagnosed with brain tumors and acute lymphoblastic leukemia. *Cancer.* 2004; 101(9):2116–25. [PubMed: 15389475]
10. Brice L, Weiss R, Wei Y, et al. Health-related quality of life (HRQoL): the impact of medical and demographic variables upon pediatric recipients of hematopoietic stem cell transplantation. *Pediatr Blood Cancer.* 2011; 57(7):1179–85. [PubMed: 21520396]
11. Johnson DL, McCabe MA, Nicholson HS, et al. Quality of long-term survival in young children with medulloblastoma. *J Neurosurg.* 1994; 80(6):1004–10. [PubMed: 8189255]
12. Reimers TS, Mortensen EL, Nysom K, Schmiegelow K. Health-related quality of life in long-term survivors of childhood brain tumors. *Pediatric Blood & Cancer.* 2009; 53(6):1086. [PubMed: 19499581]
13. Ladra ML, Edgington SK, Mahajan A, et al. A Dosimetric Comparison of Proton and Intensity Modulated Radiation Therapy in Pediatric Rhabdomyosarcoma Patients Enrolled on a Prospective Phase II Proton Study Radiotherapy and Oncology. 2014 xxx(y): xxx-xxx.
14. Lee CT, Bilton SD, Famiglietti RM, et al. Treatment planning with protons for pediatric retinoblastoma, medulloblastoma, and pelvic sarcoma: how do protons compare with other conformal techniques? *Int J Radiat Oncol Biol Phys.* 2005; 63(2):362–72. [PubMed: 16168831]
15. Yock T, Schneider R, Friedmann A, Adams J, Fullerton B, Tarbell N. Proton radiotherapy for orbital rhabdomyosarcoma: clinical outcome and a dosimetric comparison with photons. *Int J Radiat Oncol Biol Phys.* 2005; 63(4):1161–8. [PubMed: 15950401]
16. Palm A, Johansson KA. A review of the impact of photon and proton external beam radiotherapy treatment modalities on the dose distribution in field and out-of-field; implications for the long-term morbidity of cancer survivors. *Acta Oncol.* 2007; 46(4):462–73. [PubMed: 17497313]

17. Hoffman KE, Yock TI. Radiation therapy for pediatric central nervous system tumors. *J Child Neurol.* 2009; 24(11):1387–96. [PubMed: 19841427]
18. Childs SK, Kozak KR, Friedmann AM, et al. Proton Radiotherapy for Parameningeal Rhabdomyosarcoma: Clinical Outcomes and Late Effects. *Int J Radiat Oncol Biol Phys.* 2011
19. Yock TI, Yeap BY, Pulsifer MB, et al. Results from a Prospective Trial of Proton Radiotherapy for Medulloblastoma: Clinical Outcomes including Hearing and Neurocognitive. *International journal of radiation oncology, biology, physics.* 2011; 81(2):S113.
20. Kuhlthau KA, Pulsifer MB, Yeap BY, et al. Prospective study of health-related quality of life for children with brain tumors treated with proton radiotherapy. *J Clin Oncol.* 2012; 30(17):2079–86. [PubMed: 22565004]
21. Varni JW, Burwinkle TM, Seid M, Skarr D. The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity. *Ambul Pediatr.* 2003; 3(6):329–41. [PubMed: 14616041]
22. Varni JW, Burwinkle TM, Katz ER. The PedsQL in pediatric cancer pain: a prospective longitudinal analysis of pain and emotional distress. *J Dev Behav Pediatr.* 2004; 25(4):239–46. [PubMed: 15308924]
23. Varni JW, Burwinkle TM, Katz ER, Meeske K, Dickinson P. The PedsQL in pediatric cancer: reliability and validity of the Pediatric Quality of Life Inventory Generic Core Scales, Multidimensional Fatigue Scale, and Cancer Module. *Cancer.* 2002; 94(7):2090–106. [PubMed: 11932914]
24. Varni JW, Limbers CA, Burwinkle TM. Impaired health-related quality of life in children and adolescents with chronic conditions: a comparative analysis of 10 disease clusters and 33 disease categories/severities utilizing the PedsQL 4.0 Generic Core Scales. *Health Qual Life Outcomes.* 2007; 5:43. [PubMed: 17634123]
25. Bhat SR, Goodwin TL, Burwinkle TM, et al. Profile of daily life in children with brain tumors: an assessment of health-related quality of life. *J Clin Oncol.* 2005; 23(24):5493–500. [PubMed: 16110009]
26. Penn A, Lowis SP, Stevens MC, et al. Family, demographic and illness-related determinants of HRQL in children with brain tumours in the first year after diagnosis. *Pediatr Blood Cancer.* 2009; 53(6):1092–9. [PubMed: 19743518]
27. Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. *Med Care.* 2001; 39(8):800–12. [PubMed: 11468499]
28. Mulhern RK, Merchant TE, Gajjar A, Reddick WE, Kun LE. Late neurocognitive sequelae in survivors of brain tumours in childhood. *Lancet Oncol.* 2004; 5(7):399–408. [PubMed: 15231246]
29. Moeller BJ, Chintagumpala M, Philip JJ, et al. Low early ototoxicity rates for pediatric medulloblastoma patients treated with proton radiotherapy. *Radiat Oncol.* 2011; 6:58. [PubMed: 21635776]
30. McDougall J, Tsonis M. Quality of life in survivors of childhood cancer: a systematic review of the literature (2001–2008). *Support Care Cancer.* 2009; 17(10):1231–46. [PubMed: 19488790]
31. Merchant TE, Kiehna EN, Li C, et al. Modeling radiation dosimetry to predict cognitive outcomes in pediatric patients with CNS embryonal tumors including medulloblastoma. *Int J Radiat Oncol Biol Phys.* 2006; 65(1):210–21. [PubMed: 16472938]
32. Paganetti H, Athar BS, Moteabbed M, A JA, Schneider U, Yock TI. Assessment of radiation-induced second cancer risks in proton therapy and IMRT for organs inside the primary radiation field. *Phys Med Biol.* 2012; 57(19):6047–61. [PubMed: 22968191]
33. Mulhern RK, Butler RW. Neurocognitive sequelae of childhood cancers and their treatment. *Pediatr Rehabil.* 2004; 7(1):1–14. discussion 15–6. [PubMed: 14744668]

Figure 1.

(a) PedsQL scores in the proton, photon and normative cohorts (b) Total PedsQL core scores by diagnostic group and radiation type in MGH proton and LPCH photon cohorts. The bars represent the SEM (standard error of the mean).

Table 1

Patient characteristics for the MGH proton and LPCH photon pediatric brain tumor cohorts.

	MGH Protons (N=57)	LPCH Photons (N=63)	P-value
<i>Demographics</i>			
Median age at RT (Range)	7.0 (2.0-14.0)	7.7 (2.3-18.0)	0.585
Gender			0.608
Male	50.9%	55.6%	
Child's race			<0.001
White (non-hispanic)	84.2%	50.8%	
Other	15.8%	49.2%	
<i>Clinical data</i>			
Diagnosis			0.095
Medulloblastoma/PNET	33.3%	46.0%	
Ependymoma/High grade glioma	26.3%	19.1%	
Low-grade glioma	10.5%	19.1%	
Other low-grade neoplasm	17.5%	4.8%	
Germ cell tumor/Germinoma	12.3%	11.1%	
Tumor location			0.051
Posterior fossa [†]	47.4%	65.1%	
Surgery type			0.806
No surgery/Biopsy only	17.5%	15.9%	
Definitive surgery	82.5%	84.1%	
Hydrocephalus treatment			0.058
Yes (VP shunt or 3 rd ventriculostomy)	5.3%	16.1%	
No	94.7%	83.9%	
Chemotherapy			0.053
Yes	52.6%	69.8%	
Radiation Dose			0.023
< 50 Gy	10.5%	23.8%	
50-54 Gy	71.9%	71.4%	
>54 Gy	17.5%	4.8%	
Median Radiation Treatment Year	2007 (IQR, 2006-2007)	2000 (IQR, 1998-2001)	<0.001

* MGH: Massachusetts General Hospital

** LPCH: Lucile Packard Children's Hospital

[†] Posterior fossa includes Posterior fossa, 4th ventricle, brainstem, cerebellum, tectum.

Other tumor locations included 3rd ventricle, pineal, pituitary, suprasellar, supratentorial brain and thalamus.

P-values reflect the difference between the MGH and LPCH cohorts.

Table 2

Mean parent-reported PedsQL Core scores in the MGH proton and LPCH photon cohort.

Mean (SD) QOL scores	MGH Protons (N=57)	LPCH Photons (N=63)	P-value	Data from Normative Child Population [#]	P-value For difference between MGH and Normative Child Data	P-value For difference between LPCH and Normative Child Data
Total core score	75.9 (16.3)	65.4 (18.4) N=62	0.002	80.9 (16.7)	0.024	<0.001
Physical summary score	78.4 (23.4)	68.1 (22.0) N=62	0.015	81.4 (23.2)	0.337	<0.001
Psychosocial summary score	74.5 (14.9)	64.0 (18.7) N=62	0.001	80.6 (16.52)	0.003	<0.001
Emotional functioning score	76.0 (16.1)	65.8 (22.0)	0.004	77.9 (20.7)	0.377	<0.001
Social functioning score	79.7 (19.4)	63.6 (23.7) N=62	<0.001	85.4 (19.2)	0.031	<0.001
School functioning score	67.8 (20.6)	62.5 (22.3) N=53	0.197	77.8 (22.0)	<0.001	<0.001

* N's for the specific category are given below because not all patients filled out every sub category of the survey.

** Source: Varni JW, Seid M, Kurtin PS. PedsQLTM: Reliability and Validity of the Pediatric Quality of Life InventoryTM Version 4.0 Generic Core Scales in Healthy and Patient Populations. Medical Care. 2001; 39:800-812.

Table 3
Mean parent-reported PedsQL Core scores by diagnosis in the MGH* proton and LPCH† photon cohorts

	Medulloblastoma/PNET		Ependymoma/high-grade glioma		Low-grade glioma		Other low-grade neoplasm		Germ cell tumor	
	MGH n=19	LPCH n=29	MGH n=15	LPCH n=12	MGH n=6	LPCH n=12	MGH n=10	LPCH n=3	MGH n=7	LPCH n=7
<i>Total core score (SD)</i>	76.3 (14.0)	66.5 (17.7) N=28 0.050	77.1 (19.5)	59.2 (18.6) 0.023	86.7 (11.8)	63.8 (19.1) 0.017	71.2 (15.0)	56.2 (19.9) 0.182	69.4 (18.8)	78.4 (17.3) 0.372
<i>Physical summary score (SD)</i>	81.1 (18.6)	68.1 (22.5) N=28 0.044	79.6 (29.4)	66.7 (20.1) 0.206	85.4 (18.5)	65.4 (26.5) 0.119	74.0 (19.6)	58.3 (21.3) 0.257	68.8 (31.4)	79.5 (16.4) 0.439
<i>Psychosocial summary score (SD)</i>	73.8 (14.3)	66.0 (17.5) N=28 0.113	75.8 (15.2)	55.0 (20.6) 0.006	87.3 (8.7)	62.8 (16.8) 0.004	69.7 (15.5)	55.0 (19.2) 0.198	69.8 (15.9)	77.9 (18.1) 0.391
<i>Emotional functioning (SD)</i>	76.1 (15.3)	69.1 (20.2) 0.211	77.0 (16.7)	50.0 (22.0) 0.001	87.9 (14.5)	67.6 (18.1) 0.030	68.5 (18.4)	50.0 (32.8) 0.223	74.3 (12.4)	82.9 (15.2) 0.271
<i>Social functioning (SD)</i>	79.0 (13.8)	62.3 (23.1) N=28 0.003	82.7 (18.8)	57.9 (25.5) 0.008	92.5 (14.1)	62.4 (24.4) 0.014	77.5 (22.5)	65.0 (13.2) 0.388	67.1 (28.3)	80.0 (24.0) 0.377
<i>School functioning (SD)</i>	66.3 (25.5)	67.8 (19.2) N=23 0.828	67.7 (19.2)	56.7 (27.6) N=11 0.245	80.8 (17.2)	55.9 (18.2) N=10 0.017	63.0 (15.7)	50.0 (36.1) 0.365	67.9 (17.3)	70.0 (21.0) N=6 0.844
<i>Median age at follow-up</i>	10.0	10.0	10.0	10.4	14.0	10.2	10.0	13.5	14.0	16.0
<i>Follow-up (years)</i>	3.0	2.4 (median)	3.0	1.7 (median)	3.0	4.8 (median)	3.0	0.4 (median)	3.0	2.5 (median)

Note: P-values show the difference between the MGH and LPCH scores for each set of cells.